1. Home
  2. Analysis
  3. Mycophenolate-mofetil
  4. Magnevist

Mycophenolate mofetil and Magnevist drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Mycophenolate mofetil (mycophenolate mofetil) and Magnevist (gadopentetate dimeglumine). Common drug interactions include anxiety among females and nephrogenic systemic fibrosis among males.

The phase IV clinical study analyzes what interactions people have when they take Mycophenolate mofetil and Magnevist. It is created by eHealthMe based on reports of 60 people who take the same drugs from the FDA, and is updated regularly.

What is Mycophenolate mofetil?

Mycophenolate mofetil has active ingredients of mycophenolate mofetil. It is often used in myasthenia gravis. eHealthMe is studying from 93,460 Mycophenolate mofetil users. Check the latest studies of Mycophenolate mofetil.

What is Magnevist?

Magnevist has active ingredients of gadopentetate dimeglumine. eHealthMe is studying from 10,524 Magnevist users. Check the latest studies of Magnevist.

On Jul, 15, 2026

60 people who take Mycophenolate mofetil and Magnevist together, and have interactions are studied.

Mycophenolate mofetil and Magnevist drug interactions.

What are the common drug interactions of Mycophenolate Mofetil and Magnevist, by gender? *:

female:

  1. Anxiety
  2. Oedema peripheral (superficial swelling)
  3. Joint range of motion decreased (disease of joint movement)
  4. Mobility decreased (ability to move is reduced)
  5. Injury
  6. Skin tightness
  7. Skin discolouration (change of skin colour)
  8. Pain in extremity
  9. Erythema (redness of the skin)
  10. Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)

male:

  1. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
  2. Pain
  3. Muscular weakness (muscle weakness)
  4. Skin hypertrophy (skin cells enlarges)
  5. Gait disturbance
  6. Arthralgia (joint pain)
  7. Skin tightness
  8. Joint stiffness
  9. Scar
  10. Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)

What are the common drug interactions of Mycophenolate Mofetil and Magnevist, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
  2. Pain
  3. Joint range of motion decreased (disease of joint movement)
  4. Scar
  5. Anxiety
  6. Injury
  7. Joint stiffness
  8. Skin hypertrophy (skin cells enlarges)
  9. Skin induration (an abnormally hard spot or area on the skin)
  10. Arthralgia (joint pain)

30-39:

  1. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
  2. Pain
  3. Skin tightness
  4. Anxiety
  5. General physical health deterioration (weak health status)
  6. Skin induration (an abnormally hard spot or area on the skin)
  7. Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)
  8. Injury
  9. Mobility decreased (ability to move is reduced)
  10. Skin plaque (red, scaly patches to appear on the skin)

40-49:

  1. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
  2. Pain
  3. Skin induration (an abnormally hard spot or area on the skin)
  4. Oedema peripheral (superficial swelling)
  5. Skin hypertrophy (skin cells enlarges)
  6. Skin tightness
  7. Joint stiffness
  8. Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
  9. Joint range of motion decreased (disease of joint movement)
  10. Gait disturbance

50-59:

  1. Deformity (disfigurement)
  2. Dry skin
  3. Erythema (redness of the skin)
  4. Fatigue (feeling of tiredness)
  5. Gait disturbance
  6. Hip fracture
  7. Joint range of motion decreased (disease of joint movement)
  8. Muscle tightness
  9. Oedema (fluid collection in tissue)
  10. Pain in extremity

60+:

  1. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
  2. Pain
  3. General physical health deterioration (weak health status)
  4. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  5. Gait disturbance
  6. Abasia (inability to walk)
  7. Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)
  8. Joint range of motion decreased (disease of joint movement)
  9. Pain in extremity
  10. Scar

What are the existing conditions these people have? *

  1. Nuclear Magnetic Resonance Imaging Brain: 24 people, 40.00%
  2. Nuclear Magnetic Resonance Imaging Abdominal: 19 people, 31.67%
  3. Pain: 5 people, 8.33%
  4. High Blood Pressure: 4 people, 6.67%
  5. Renal Artery Stenosis (narrowing of renal artery): 3 people, 5.00%
  6. Haemorrhage Intracranial (bleeding within the skull): 3 people, 5.00%
  7. Diabetes: 3 people, 5.00%
  8. Coronary Heart Disease (narrowing or blockage of the coronary arteries): 3 people, 5.00%
  9. Chronic Renal Failure (kidney failure): 3 people, 5.00%
  10. Cardiac Failure Congestive: 3 people, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Mycophenolate mofetil and Magnevist?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Mycophenolate mofetil and Magnevist:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Mycophenolate mofetil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Magnevist:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Mycophenolate mofetil and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Magnevist and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on mycophenolate mofetil and gadopentetate dimeglumine (the active ingredients of Mycophenolate mofetil and Magnevist, respectively), and Mycophenolate mofetil and Magnevist (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.